MS9427 (TFA)

• Description:

  MS9427 TFA is a potent PROTAC EGFR degrader with Kds of 7.1 nM and 4.3 nM for EGFR WT and EGFR L858R, respectively. MS9427 TFA selectively degrades the mutant but not the WT EGFR through both the ubiquitin/proteasome system (UPS) and autophagy/lysosome pathways. MS9427 TFA potently inhibits the proliferation of NSCLC cells. MS9427 TFA can be used for researching anticancer[1].

• UNSPSC:

  12352005

• Target:

  EGFR; PROTACs

• Type:

  Reference compound

• Related Pathways:

  JAK/STAT Signaling; PROTAC; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ms9427-tfa.html

• Purity:

  98.38

• Solubility:

  DMSO : 150 mg/mL (ultrasonic)

• Smiles:

  O=C1N (C (CC2) C (NC2=O) =O) C (C3=C1C=CC (NCCOCCOCCOCCOCCOCCC (N4CCN (CCCOC5=CC6=C (NC7=CC=C (F) C (Cl) =C7) N=CN=C6C=C5OC) CC4) =O) =C3) =O.OC (C (F) (F) F) =O

• Molecular Formula:

  C50H59ClF4N8O14

• Molecular Weight:

  1107.50

• References & Citations:

  [1]Yu X, et al. Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras. J Med Chem. 2022 Jun 23;65 (12) :8416-8443.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported